Lisa is a stock analyst with nearly 25 years of investment research experience. She earned a MBA in Finance from the University of Chicago in 1987 and began her career in investment research that same year as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of director of financial analysis.
During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy and other Fortune 1000 companies. In 2000, Lisa left to become director of investor Relations for a NYSE-listed REIT, serving in that position until the REIT was acquired. Since then, Lisa has worked as a stock analyst for independent research firms, investment newsletters and financial websites.
Analyst Articles
If you’re like most Americans, you probably own a pet and spend hundreds of dollars each year to keep your furry friend happy and healthy. As it turns out, man’s best friend can also be an intriguing investment angle. Last year alone, Americans spent $48.3 billion on their pets, including… Read More
Income investors are like anyone else when it comes to getting paid: they’d rather get paid sooner rather than later. But unlike some, they have a good reason for it. Because of inflation, money is always worth more now than later. Plus, money you get now… Read More
I recently heard from a reader who wondered aloud why shares of LDK Solar (NYSE: LDK), which have lost half of their value since early May — and 90% of their value since 2007 — are trading so poorly. After all, this major player in the solar industry has… Read More
Here are three stocks with Game-Changer potential trading at fire-sale prices. Read More
I’ve been in the investing business a long time. I’ve witnessed two nasty bear markets and three bull markets, including the massive one from the 1990s. I’ve seen a technology boom then bust, a collapse of the… Read More
It’s really tempting to fill your portfolio with biotech stocks. This is because biotech investors who find the next breakthrough stock are able to double, triple or quadruple their money almost overnight. Take Dendreon (Nasdaq: DNDN), a maker of a pricey prostate cancer drug, for instance. As… Read More
If you’ve been looking at a sea of red on your stock screens lately, then you have plenty of company. A hefty 495 stocks in the S&P 500 have moved lower since the market sell-off began July 22. Yet a quick look at the five lonely stocks that have been… Read More
When it comes to stock buybacks, we tend to assume investors will surely benefit sooner and later. In the near-term, shares can find support from a large institutional buyer — i.e. the company itself — and in the long-term, earnings per share… Read More
Most of the time, value investors look for stocks that have a price-to-earnings (P/E) ratio that is less than the earnings growth rate, or a PEG ratio below 1. For example, a stock with a P/E of 15 and an… Read More
Editor’s note: As has been widely reported, Warren Buffett this morning (August 25) announced plans to invest $5 billion in Bank of America (NYSE: BAC). According to reports, Buffett will buy 50,000 preferred shares paying a 6% annual… Read More
